This continuing feature will update readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number one killer in the US, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, pharmacists can have a significant impact on prevention and treatment — if they keep current with developments in drug therapy.
Get full access to this article
View all access options for this article.
References
1.
DagerW.E., WhiteR.H.Treatment of heparin-induced thrombocytopenia. Ann Pharmacother.2002; 36: 489–503.
2.
WarkentinT.E.Heparin-induced thrombocytopenia, Part 1: The diagnostic clues. J Crit Illness.2002; 17(5): 172–8.
3.
WarkentinT.E.Heparin-induced thrombocytopenia, Part 2: Clinical course and treatment. J Crit Illness.2002; 17(6): 215–22.
4.
WarkentinT.E.Heparin-induced thrombocytopenia: Pathogenesis and management. Br J Haematol.2003; 121: 535–55.
5.
WarkentinT.E., BarkinR.L.Newer strategies for the treatment of heparin-induced thrombocytopenia. Pharmacotherapy.1999; 19: 181–95.
6.
WarkentinT.E., SigouinC.S.Gender and risk of immune heparin-induced thrombocytopenia. Blood.2002; 100: 17a.
7.
WarkentinT.E., KeltonJ.G.Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med.2001; 344: 1286–92.
8.
RiceL., AttishaW.K., DrexlerA.Delayed-onset, heparin-induced thrombocytopenia. Ann Intern Med.2002; 136: 210–15.
9.
GirolamiB., PrandoniP., StefaniP.M.The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: A prospective cohort study. Blood.2003; 101: 2955–9.
10.
HirshJ., WarkentinT.E., ShaughnessyS.G.Heparin and low-molecular weight heparin. Sixth Consensus Conference on Antithrombotic Therapy. Chest.2001; 119: 64S–94S.
11.
WarkentinT.E., KeltonJ.G.A 14-year study of heparin-induced thrombocytopenia. Am J Med.1996; 101: 502–7.
12.
MagnaniH.N.Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost.1993; 70:554–61. Erratum: Thromb Haemost. 1993; 70: 1072.
13.
GreinacherA., VolpelH., JanssensU.for the HIT Investigators Group. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation.1999; 99: 73–80.
14.
GreinacherA., JanssensU., BergG.for the Heparin-Associated Thrombocytopenia Study (HAT) Investigators. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation.1999; 100: 587–93.
15.
GreinacherA., EichlerP., LubenowN.Heparin-induced thrombocytopenia with thromboembolic complications: Meta-analysis of two prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood.2000; 96: 846–51.
16.
SmytheM.A., WarkentinT.E.Comment: Treatment of heparin-induced thrombocytopenia [letter]. Ann Pharmacother.2002; 36: 1483–4.
17.
EichlerP., Heinz-JuergenF., LubenowN.Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: Incidence, effects on aPTT and clinical relevance. Blood.2000; 96: 2373–8.
18.
LewisB.E., WallisD.E., LeyaF.Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med.2003; 163: 1849–56.
19.
Argatroban [product information].Research Triangle, NC: Glaxo Smith Kline; July 2003.
20.
ShethS.B., DiCiccoR.A., HurstingM.J.Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost.2001; 85: 435–40. Erratum: Thromb Haemost. 2001; 86: 727.
21.
VasquezJ.C., VichiendilokkulA., MahmoodS.Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery. Ann Thorac Surg.2002; 74: 2177–9.
22.
BottJ.N., ReddyK., KrickS.Bivalirudin use in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia. Ann Thorac Surg.2003; 76: 273–5.
23.
DavisZ., AndersonR., ShortD.Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass. Ann Thorac Surg.2003; 75: 264–5.
24.
MahaffeyK.W., LewisB.E., WildermannN.M.ATBAT Investigators. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: Main results. J Invasive Cardiol.2003; 15: 611–6.
25.
GordonG., RastegarH., SchumannR.Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth.2003; 17: 632–5.
26.
SciulliT.M., MauroV.F.Pharmacology and clinical use of bivalirudin. Ann Pharmacother.2002; 36: 1028–41.
27.
WarkentinT.E., GreinacherA.Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg.2003; 76: 2121–31.
28.
SrinivasanA.F., RiceL., BartholomewJ.R.Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med.2004; 164: 66–70.
29.
WilliamsR.T., DamarajuL.V., MascelliM.A.Anti-platelet factor 4/heparin antibodies. An independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation.2003; 107: 2307–12.
30.
MattioliA.V., BonettiL., SternieriS.Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: Prevalence of thrombosis in a 1-year follow-up. Ital Heart J.2000; 1: 39–42.
31.
LiuJ.C., LewisB.E., SteenL.H.Patency of coronary artery bypass grafts in patients with heparin-induced thrombocytopenia. Am J Cardiol.2002; 89: 979–81.
